TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04310748
Drug: Inhalation Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded.
Study: NCT03494205
Drug: institutional standard skin care Excipial-Hydrolotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The institutional standard skin care Excipial-Hydrolotion is available to all patients
Study: NCT01456689
Drug: LGH447
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02117479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tablets to be administered by mouth twice daily (BID)
Study: NCT02900183
Drug: ARC-AAT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA interference (RNAi)-based, liver-targeted therapeutic
Study: NCT01052896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Look-alike of gabapentin 300mg given po tid
Study: NCT00497783
Drug: Lactoserum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00685685
Drug: Lovastatin 40 mg tablets
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet administered after an overnight fast of at least 10 hours
Study: NCT00685685
Drug: Lovastatin (Mevacor®) 40 mg Tablets
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet administered after an overnight fast of at least 10 hours
Study: NCT02117479
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 and 500 mg tablets to be administered by mouth twice daily (BID)
Study: NCT04386915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
Study: NCT00647218
Drug: neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
Study: NCT01275339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
Study: NCT01561027
Drug: CNV1014802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in treatment arm.
Study: NCT01561027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in treatment arm
Study: NCT02981602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04029116
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID (one day) every 4 weeks for a total of 6 dosing days
Study: NCT04198727
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
Study: NCT00321061
Drug: VRC-HIVDNA016-00, VRC-HIVADV014-00
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00494598
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mcg intra-arterial one time bolus
Study: NCT04190433
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04190433
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04280536
Drug: Cohort A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Study: NCT04280536
Drug: Cohort B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Study: NCT03882775
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin with or without gpi during emergency PCI.
Study: NCT01196039
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT01762462
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT01689909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
Study: NCT03350984
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
Study: NCT00771004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
Study: NCT02183155
Drug: Meloxicam - low
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183155
Drug: Meloxicam - medium
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183155
Drug: Meloxicam - high
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183155
Drug: Extended-release indomethacin
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03628924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
Study: NCT01572506
Drug: Biotin RBC survival
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04198818
Drug: HH2710
Approvals — FDA: no, EMA: no, PMDA: no
Description: HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
Study: NCT04066244
Drug: BLZ945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug capsules taken orally or via enteral infusion
Study: NCT00766441
Drug: sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphonylurea, variable, od or bd, during ramadan
Study: NCT03023046
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03023046
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01600742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
Study: NCT04682873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed.
Study: NCT01879527
Drug: Amiloride hydrochlorothiazide
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
Study: NCT02607449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without any active pharmaceutical ingredients
Study: NCT00664027
Drug: RTA 402 (Bardoxolone Methyl)
Normalized name: METHYLAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
Study: NCT03818919
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03818919
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03818919
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT00582283
Drug: I124-NM404
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-124-NM404
Study: NCT00240305
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04005339
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
Study: NCT04005339
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 2,400 mg/m IV over 46 hours.
Study: NCT02477267
Drug: SL spray
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02245360
Drug: Phleum pratense grass pollen allergen extract
Normalized name: Phleum pratense allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
Study: NCT02442349
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet 80 mg
Study: NCT01539083
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 300 mg/m\^2 orally.
Study: NCT01539083
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 50 mg orally.
Study: NCT04243109
Drug: Pomalidomide + Cyclophosphamide + Dexamethasone
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained.
Study: NCT01788176
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
Study: NCT01788176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single intravenous infusion of 100ml of saline.
Study: NCT00882310
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
Study: NCT04542161
Drug: NAC 900mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: self administer NAC 900mg/day caplets for a four week period
Study: NCT04542161
Drug: NAC 3600mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: self administer NAC 3600mg/day caplets for a four week period
Study: NCT04542161
Drug: NAC 0mg/day (Placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: self administer NAC 0mg/day (placebo) caplets for a four week period
Study: NCT00472173
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apexification treatment of the tooth with Calcium hydroxide
Study: NCT03444714
Drug: RiMO-301
Normalized name: Rimoxyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks
Study: NCT04252859
Drug: [18F]Fluoroestradiol (FES) PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
Study: NCT00601705
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
Study: NCT06105619
Drug: PLB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1001 is a capsule in the form of 300mg,twice daily.
Study: NCT01127945
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy
Study: NCT02673606
Drug: Estradiol 2Mg Tablet
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
Study: NCT02673606
Drug: Estradiol 4Mg Tablet
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
Study: NCT04171531
Drug: Botox® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
Study: NCT02651714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01646294
Drug: YM178 modified release (OCAS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01646294
Drug: YM178 immediate release (IR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01515540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01597388
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
Study: NCT04494815
Drug: SR419 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive 2 doses of SR419 placebo oral suspension.
Study: NCT04494815
Drug: active control placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive 2 doses of active control placebo capsule.
Study: NCT04251156
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Study: NCT02285283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06293261
Drug: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental only, not included active and placebo comparator
Study: NCT02477423
Drug: Gentamicins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
Study: NCT02477423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be given as placebo for those in the placebo comparator group.
Study: NCT03956355
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied once daily
Study: NCT00708201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02179671
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 once daily followed by MEDI4736
Study: NCT00696475
Drug: Diazoxide choline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03463369
Drug: Nucleos(t)ide Analogs (NA)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NA as a standard of care treatment.
Study: NCT02964403
Drug: Cox-2
Normalized name: COX-2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02964403
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02546765
Drug: IV acetaminophen & IV propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of IV tylenol and IV propofol for pain and sedation (respectively)
Study: NCT02546765
Drug: IV acetaminophen & IV dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
Study: NCT01395251
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 20 mg once a day per os for 3 subsequent days
Study: NCT04218123
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral intake
Study: NCT00396747
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00396747
Drug: Methotrexate + Methylprednisolone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02064920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for donepezil hydrochloride capsule
Study: NCT00579436
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 inert capsules daily by mouth for 12 weeks.
Study: NCT01299701
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Description: (5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
Study: NCT04679545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive compound.
Study: NCT01147016
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As prescribed by physician, standard of care.
Study: NCT01147016
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prescribed by physician, standard of care.
Study: NCT03791918
Drug: TACE Drug Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Study: NCT02024646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via subcutaneous injection until week 24.
Study: NCT01271933
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet; given once daily
Study: NCT02059187
Drug: MK-1293
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.